CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is actually  a   biotech which has proved helpful diligently but unsuccessfully to produce an one-time therapy, variously named Pro 140, leronlimab, and Vyrologix.

In development of this particular therapy, CytoDyn has cast its net wide and far both geographically and in terminology of possible indications.

CytoDyn’s inventories of leronlimab are building up, whether they will ever be used is an open question.

While CYDY  happens to be dawdling, market opportunities for leronlimab as being a combination treatment in the healing of multi-drug-resistant HIV are actually closing.

I am composing my fifteenth CytoDyn (OTCQB:CYDY) article on FintechZoom to celebrate the sale of my last several shares. My first CytoDyn article, “CytoDyn: What To Do When It’s Too Good In order to Be True?”, set away all of the following prediction:

Instead I expect it to be a serial disappointer. CEO Pourhassan presented such a very marketing picture in the Uptick Newswire interview that I came away with a poor viewpoint of the business.

Irony of irony, my poor opinion of the business has grown steadily, although the disappointment has not been financial. 2 years ago CytoDyn was trading <$1.00. On 2/19/20 as I create, it trades at $5.26; my closing transaction was on 2/11/21 > $6.00.

What manner of stock  is it that gives a > 6 bagger yet still disappoints? Therein lies the story; allow me to explain.

CytoDyn acquired its much storied therapy (which I shall relate to as leronlimab) back during 2012, announced as follows:

CytoDyn Inc…. has completed the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) focusing on the CCR5 receptor for the therapy as well as reduction of HIV, coming from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is a late Stage II clinical development mAb with demonstrated anti viral activity of HIV- infected subjects. Today’s payment of $3.5 huge number of transfers ownership of the know-how and also connected intellectual property coming from Progenics to CytoDyn, as well as approximately 25 million mg of majority drug substance…. milestone payments after commencement of a level III clinical trial ($1.5 huge number of) along with the very first brand new drug application approval ($five million), and also royalty payments of five percent of net sales after commercialization.

Since that moment, CytoDyn’s leading nous, Nader Pourhassan [NP] has transformed this inauspicious acquisition right into a springboard for CytoDyn to buy a market cap > $3.5 billion. It’s done so in premium reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

As opposed to having a pipeline with multiple therapies and many indications, it’s this individual therapy in addition to a “broad pipeline of indications” since it puts it. I call some pipelines, “pipedots.” In CytoDyn’s case it touts its leronlimab as a likely advantageous therapy in dozens of indications.

Its opening banner on the website of its (below) shows an energetic organization with diverse interests albeit centered on leronlimab, multiple disease types, multiple publications and multiple delivering presentations.

Could all of it be smoke cigarettes and mirrors? That’s a question I’ve been asking myself from the really start of the interest of mine in this particular business. Judging by the multiples of a huge number of diverse comments on listings accessible through Seeking Alpha’s CytoDyn Summary webpage, I am far from alone in this particular question.

CytoDyn is a traditional battleground, or perhaps some could say cult inventory. Its adherents are fiercely shielding of the prospects of its, quick to label some bad opinions as scurrilous short mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News